FABP5 and metabolic dysfunction-associated steatotic liver disease: Gene‐expression changes associated with NAFLD/NASH development were observed, including increased expression of genes associated with insulin resistance (e.g., IGF1, IGFB139), glucose metabolism (e.g., G6PD,40 PDK441), and lipid metabolism (e.g., FABP5,42 LPL43).